Pharmafile Logo

B2B sales

- PMLiVE

China’s BeiGene takes PD-1 antibody into pivotal trials

Firm aims to leapfrog immunotherapy leaders in huge market

- PMLiVE

Sangamo bulks up in cell therapy with TxCell acquisition

Hopes to start cell-based immunotherapy trials next year

- PMLiVE

Merck & Co joins big pharma pricing pledge – but sceptics unconvinced

Large portfolios gives companies room for manoeuvre

- PMLiVE

Aurora partners with PIPHealth and taps into patient panels

Becomes the first strategic communications agency with its own patient panel

- PMLiVE

FDA’s Gottlieb lambasts industry’s biosimilar-blocking tactics

Speech coincides with Biosimilars Action Plan

- PMLiVE

Allergan’s abicipar matches AMD blockbuster Lucentis in phase III

Bayer's Eylea remains the drug to beat, however

AstraZeneca AZ

AstraZeneca joins Merck in Brexit stockpiling effort

Says it is increasing stores of medicines by around 20%

- PMLiVE

Vyriad inks immunotherapy alliance with Merck/Pfizer

Genetically engineered virus produces immune response in tumours

- PMLiVE

Huntsworth buys Giant Creative Strategy

New acquisition will expand Huntsworth’s reach

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links